AVN 101
Alternative Names: AVN-101; CD 008 0045Latest Information Update: 27 Sep 2022
At a glance
- Originator ChemDiv
 - Developer AllaChem; Avineuro Pharmaceuticals; ChemDiv
 - Class Antidementias; Indoles; Neuroprotectants; Pyridines; Small molecules
 - Mechanism of Action Adrenergic receptor antagonists; Dopamine receptor antagonists; Histamine receptor antagonists; Serotonin 6 receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase II Alzheimer's disease; Anxiety disorders
 
Most Recent Events
- 27 Sep 2022 No development reported - Phase-II for Anxiety disorders in Russia (PO)
 - 22 Dec 2020 Chemical structure information added
 - 22 Oct 2020 Avineuro Pharmaceuticals and Avineuro Pharmaceuticals plans a phase III trial in Anxiety disorders in December 2020 (PO, Capsules) (NCT04598867)